Analysis of peripheral blood from a patient with colorectal cancer who responded rapidly to pembrolizumab treatment showed high expression of CD39 on CD8+ TILs, indicating that CD39+CD8+TIL may be a promising predictive biomarker [86]. This evidence concerns the gene CD8A and colorectal cancer.